Jeff Meacham

“Michael, just maybe a broader question on the Glyph platform. I know as you go from Phase I, II to pivotal studies, your exposure is going to, you know, is going to increase dramatically the number of investments and number of patients.”

“The first, I know the focus on oligomers obviously differentiates you from Kisanla and McKimby, but how would you set expectations on safety and tolerability and the differences there, I guess particularly as we get more real-world experience with these two agents commercially?”

“So we've seen a big step up in pharma to biotech M&A, and maybe there's some pharma to pharma M&A to come. The question is, what is the flexibility to tilt your deal structure with increasing weight on equity?”